Paion AG Company Profile - Aug 16, 2011 by WrightReports

VIEWS: 11 PAGES: 9

Paion AG is a Germany-based pharmaceutical holding company. It develops and commercializes drugs for the treatment of strokes and problems relating to the central nervous system, as well as other thrombotic and cardiovascular diseases. Paion AG's core activity is the advancement of drug candidates, both purchased and licensed in-house, through the clinical development phases and regulatory approval process. The Company has several products which finished the Phase III stage of clinical trials, including Desmoteplase, a blood clot-dissolving plasminogen activator for treating acute ischemic strokes and M6G, an active potent metabolite of morphine for treating post-operative pain. It has also products in Phase II (CNS 7056 and `Flovagatran) and in Phase I, like Solulin. Paion AG operates worldwide through partnership with H. Lundbeck A/S. As of December 31, 2009, the Company has seven wholly-owned and consolidated subsidiaries worldwide

More Info
									Company Fundamentals\Company Profile

   A Wright Investors' Service Research Report:

   Paion AG
                                                                                         440 Wheelers Farms Road
                                                                                         Milford, CT 06461 U.S.A.


  COMPANY PROFILE
  Figures in Euro

                                 Wright Quality Rating:LCNN                                 Key Data

   Paion AG is a Germany-based pharmaceutical holding company. It develops and              Ticker:
   commercializes drugs for the treatment of strokes and problems relating to the           PA8
   central nervous system, as well as other thrombotic and cardiovascular diseases.
   Paion AG's core activity is the advancement of drug candidates, both purchased and       2010 Sales:
   licensed in-house, through the clinical development phases and regulatory approval
                                                                                            4,474,000
   process. The Company has several products which finished the Phase III stage of
   clinical trials, including Desmoteplase, a blood clot-dissolving plasminogen activator
   for treating acute ischemic strokes and M6G, an active potent metabolite of              Major Industry:
   morphine for treating post-operative pain. It has also products in Phase II (CNS 7056    Drugs, Cosmetics & Health
   and `Flovagatran) and in Phase I, like Solulin. Paion AG operates worldwide through      Care
   partnership with H. Lundbeck A/S. As of December 31, 2009, the Company has
   seven wholly-owned and consolidated subsidiaries worldwide                               Sub Industry:
                       Stock Chart                                    Officers              Ethical Drug Manufacturers
                                                                     Chairman
                                                              Dr. Joerg Spiekerkoetter      Country:
                                                                                            Germany
                                                         Chairman, Chief Executive &
                                                           Chief Operating Officer   Currency:
                                                            Dr. Wolfgang Soehngen
                                                                                     Euro

                                                         Vice Chairman, Supervisory
                                                                                            Fiscal Year Ends:
                                                                    Board
                                                              Dr. Harald F. Stock           December


                                                              Chief Financial Officer       Employees
                                                                  Bernhard Hofer            27

                                                                                            Exchanges:
                                                                                            FRA

                                                                                            Share Type:
                                                                                            Stammaktie

             Stock Price (8/12/2011): 1.69
                                                                                            Market Capitalization:
               Recent stock performance
                                                                                            42,859,711
                  1 Week        8.3%
                  4 Weeks     -19.5%
                  13 Weeks    -24.7%                                                        Total Shares
           
								
To top